Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Posts $178,000 in Q2 Revenues on Sales of Aura Device

Premium

Verisante Technology last week reported second quarter revenues of C$178,000 ($170,000), all from sales of its Aura skin cancer detection device.

The figure follows on C$235,000 in revenues from Aura sales that the company reported in the first quarter of this year. The company launched sales of the device, which uses Raman spectroscopy to distinguish benign skin legions from malignant lesions, in January (PM 2/1/2013).

For the quarter, Verisante posted a loss of C$1.14 million and a loss of C$0.02 per share. Expenses were up 79 percent from to C$1.2 million from C$668,465 in Q2 2012. This rise, the company said, was due mainly to increases in salaries and office expenses as it added personnel and leased additional office and manufacturing space as past of its ongoing expansion of operations.

As of June, 30, Verisante had C$1.02 million in cash.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.